A detailed history of First Horizon Corp transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, First Horizon Corp holds 770 shares of HALO stock, worth $51,181. This represents 0.0% of its overall portfolio holdings.

Number of Shares
770
Holding current value
$51,181
% of portfolio
0.0%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Oct 24, 2025

BUY
$52.92 - $78.28 $40,748 - $60,275
770 New
770 $56,000

Others Institutions Holding HALO

About HALOZYME THERAPEUTICS, INC.


  • Ticker HALO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 139,288,992
  • Market Cap $9.26B
  • Description
  • Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...
More about HALO
Track This Portfolio

Track First Horizon Corp Portfolio

Follow First Horizon Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of First Horizon Corp, based on Form 13F filings with the SEC.

News

Stay updated on First Horizon Corp with notifications on news.